The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Sickle Cell Disease Treatments Market Research Report 2025
Synopsis
Sickle Cell Disease (SCD) is a group of blood disorders typically inherited from a person's parents.
The global Sickle Cell Disease Treatments market was valued at US$ 423.4 million in 2023 and is anticipated to reach US$ 602.6 million by 2030, witnessing a CAGR of 5.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Sickle Cell Disease Treatments, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sickle Cell Disease Treatments.
Report Scope
The Sickle Cell Disease Treatments market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sickle Cell Disease Treatments market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sickle Cell Disease Treatments companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Eli Lilly
Bristol-Myers Squibb
Novartis
Pfizer
Baxter
Emmaus Life Sciences
Bluebird Bio
Global Blood Therapeutics
Sangamo Therapeutics
Acceleron Pharma
Arena Pharmaceuticals
Alnylam Pharmaceuticals
Segment by Type
Infection Prevention with Vaccination and Antibiotics
Blood Transfusion
The Medication Hydroxycarbamide
A Transplant of Bone Marrow Cells
Segment by Application
Hospitals
Ambulatory Surgical Centers
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sickle Cell Disease Treatments companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Sickle Cell Disease (SCD) is a group of blood disorders typically inherited from a person's parents.
The global Sickle Cell Disease Treatments market was valued at US$ 423.4 million in 2023 and is anticipated to reach US$ 602.6 million by 2030, witnessing a CAGR of 5.1% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Sickle Cell Disease Treatments, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sickle Cell Disease Treatments.
Report Scope
The Sickle Cell Disease Treatments market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sickle Cell Disease Treatments market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sickle Cell Disease Treatments companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AstraZeneca
Eli Lilly
Bristol-Myers Squibb
Novartis
Pfizer
Baxter
Emmaus Life Sciences
Bluebird Bio
Global Blood Therapeutics
Sangamo Therapeutics
Acceleron Pharma
Arena Pharmaceuticals
Alnylam Pharmaceuticals
Segment by Type
Infection Prevention with Vaccination and Antibiotics
Blood Transfusion
The Medication Hydroxycarbamide
A Transplant of Bone Marrow Cells
Segment by Application
Hospitals
Ambulatory Surgical Centers
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sickle Cell Disease Treatments companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Sickle Cell Disease Treatments Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Infection Prevention with Vaccination and Antibiotics
1.2.3 Blood Transfusion
1.2.4 The Medication Hydroxycarbamide
1.2.5 A Transplant of Bone Marrow Cells
1.3 Market by Application
1.3.1 Global Sickle Cell Disease Treatments Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals
1.3.3 Ambulatory Surgical Centers
1.3.4 Clinics
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sickle Cell Disease Treatments Market Perspective (2019-2030)
2.2 Sickle Cell Disease Treatments Growth Trends by Region
2.2.1 Global Sickle Cell Disease Treatments Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Sickle Cell Disease Treatments Historic Market Size by Region (2019-2024)
2.2.3 Sickle Cell Disease Treatments Forecasted Market Size by Region (2025-2030)
2.3 Sickle Cell Disease Treatments Market Dynamics
2.3.1 Sickle Cell Disease Treatments Industry Trends
2.3.2 Sickle Cell Disease Treatments Market Drivers
2.3.3 Sickle Cell Disease Treatments Market Challenges
2.3.4 Sickle Cell Disease Treatments Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sickle Cell Disease Treatments Players by Revenue
3.1.1 Global Top Sickle Cell Disease Treatments Players by Revenue (2019-2024)
3.1.2 Global Sickle Cell Disease Treatments Revenue Market Share by Players (2019-2024)
3.2 Global Sickle Cell Disease Treatments Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Sickle Cell Disease Treatments Revenue
3.4 Global Sickle Cell Disease Treatments Market Concentration Ratio
3.4.1 Global Sickle Cell Disease Treatments Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sickle Cell Disease Treatments Revenue in 2023
3.5 Sickle Cell Disease Treatments Key Players Head office and Area Served
3.6 Key Players Sickle Cell Disease Treatments Product Solution and Service
3.7 Date of Enter into Sickle Cell Disease Treatments Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Sickle Cell Disease Treatments Breakdown Data by Type
4.1 Global Sickle Cell Disease Treatments Historic Market Size by Type (2019-2024)
4.2 Global Sickle Cell Disease Treatments Forecasted Market Size by Type (2025-2030)
5 Sickle Cell Disease Treatments Breakdown Data by Application
5.1 Global Sickle Cell Disease Treatments Historic Market Size by Application (2019-2024)
5.2 Global Sickle Cell Disease Treatments Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Sickle Cell Disease Treatments Market Size (2019-2030)
6.2 North America Sickle Cell Disease Treatments Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Sickle Cell Disease Treatments Market Size by Country (2019-2024)
6.4 North America Sickle Cell Disease Treatments Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Sickle Cell Disease Treatments Market Size (2019-2030)
7.2 Europe Sickle Cell Disease Treatments Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Sickle Cell Disease Treatments Market Size by Country (2019-2024)
7.4 Europe Sickle Cell Disease Treatments Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Sickle Cell Disease Treatments Market Size (2019-2030)
8.2 Asia-Pacific Sickle Cell Disease Treatments Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Sickle Cell Disease Treatments Market Size by Region (2019-2024)
8.4 Asia-Pacific Sickle Cell Disease Treatments Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Sickle Cell Disease Treatments Market Size (2019-2030)
9.2 Latin America Sickle Cell Disease Treatments Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Sickle Cell Disease Treatments Market Size by Country (2019-2024)
9.4 Latin America Sickle Cell Disease Treatments Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sickle Cell Disease Treatments Market Size (2019-2030)
10.2 Middle East & Africa Sickle Cell Disease Treatments Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Sickle Cell Disease Treatments Market Size by Country (2019-2024)
10.4 Middle East & Africa Sickle Cell Disease Treatments Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AstraZeneca
11.1.1 AstraZeneca Company Detail
11.1.2 AstraZeneca Business Overview
11.1.3 AstraZeneca Sickle Cell Disease Treatments Introduction
11.1.4 AstraZeneca Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.1.5 AstraZeneca Recent Development
11.2 Eli Lilly
11.2.1 Eli Lilly Company Detail
11.2.2 Eli Lilly Business Overview
11.2.3 Eli Lilly Sickle Cell Disease Treatments Introduction
11.2.4 Eli Lilly Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.2.5 Eli Lilly Recent Development
11.3 Bristol-Myers Squibb
11.3.1 Bristol-Myers Squibb Company Detail
11.3.2 Bristol-Myers Squibb Business Overview
11.3.3 Bristol-Myers Squibb Sickle Cell Disease Treatments Introduction
11.3.4 Bristol-Myers Squibb Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.3.5 Bristol-Myers Squibb Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Sickle Cell Disease Treatments Introduction
11.4.4 Novartis Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 Pfizer
11.5.1 Pfizer Company Detail
11.5.2 Pfizer Business Overview
11.5.3 Pfizer Sickle Cell Disease Treatments Introduction
11.5.4 Pfizer Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.5.5 Pfizer Recent Development
11.6 Baxter
11.6.1 Baxter Company Detail
11.6.2 Baxter Business Overview
11.6.3 Baxter Sickle Cell Disease Treatments Introduction
11.6.4 Baxter Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.6.5 Baxter Recent Development
11.7 Emmaus Life Sciences
11.7.1 Emmaus Life Sciences Company Detail
11.7.2 Emmaus Life Sciences Business Overview
11.7.3 Emmaus Life Sciences Sickle Cell Disease Treatments Introduction
11.7.4 Emmaus Life Sciences Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.7.5 Emmaus Life Sciences Recent Development
11.8 Bluebird Bio
11.8.1 Bluebird Bio Company Detail
11.8.2 Bluebird Bio Business Overview
11.8.3 Bluebird Bio Sickle Cell Disease Treatments Introduction
11.8.4 Bluebird Bio Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.8.5 Bluebird Bio Recent Development
11.9 Global Blood Therapeutics
11.9.1 Global Blood Therapeutics Company Detail
11.9.2 Global Blood Therapeutics Business Overview
11.9.3 Global Blood Therapeutics Sickle Cell Disease Treatments Introduction
11.9.4 Global Blood Therapeutics Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.9.5 Global Blood Therapeutics Recent Development
11.10 Sangamo Therapeutics
11.10.1 Sangamo Therapeutics Company Detail
11.10.2 Sangamo Therapeutics Business Overview
11.10.3 Sangamo Therapeutics Sickle Cell Disease Treatments Introduction
11.10.4 Sangamo Therapeutics Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.10.5 Sangamo Therapeutics Recent Development
11.11 Acceleron Pharma
11.11.1 Acceleron Pharma Company Detail
11.11.2 Acceleron Pharma Business Overview
11.11.3 Acceleron Pharma Sickle Cell Disease Treatments Introduction
11.11.4 Acceleron Pharma Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.11.5 Acceleron Pharma Recent Development
11.12 Arena Pharmaceuticals
11.12.1 Arena Pharmaceuticals Company Detail
11.12.2 Arena Pharmaceuticals Business Overview
11.12.3 Arena Pharmaceuticals Sickle Cell Disease Treatments Introduction
11.12.4 Arena Pharmaceuticals Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.12.5 Arena Pharmaceuticals Recent Development
11.13 Alnylam Pharmaceuticals
11.13.1 Alnylam Pharmaceuticals Company Detail
11.13.2 Alnylam Pharmaceuticals Business Overview
11.13.3 Alnylam Pharmaceuticals Sickle Cell Disease Treatments Introduction
11.13.4 Alnylam Pharmaceuticals Revenue in Sickle Cell Disease Treatments Business (2019-2024)
11.13.5 Alnylam Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
